Golden
BlueRock Therapeutics

BlueRock Therapeutics

A biotechnology company developing engineered cell therapies for treating diseases in neurology, cardiology and autoimmunity.

BlueRock Therapeutics is a biotechnology company headquartered in New York City, New York that was founded by Lorenz Studer, Gordon Keller, Michael Laflamme, and Viviane Tabar. 

Products

BlueRock is using their Cell plus Gene platform to produce cell therapies for replacement of damaged or degenerated tissue. BlueRock’s neurology pipeline focuses on Parkinson’s Disease and engineering microglia for other neurological disorders. Their cardiology pipeline includes cell therapy for heart failure using cardiomyocytes. For autoimmune diseases, the company is designing macrophage cell therapies. BlueRock is using ex vivo engineering to enable cells to produce enzymes, antibodies and other proteins with therapeutic benefit. 



Cell therapy candidates are based on induced pluripotent stem (IPS) cell technology.  The company’s approach is based on iPSC intellectual property invented by Shinya Yamanaka of Kyoto University in Japan and licensed from iPS Academia Japan, which manages iPSC IP. 

Partnerships

Memorial Sloan Kettering Cancer Center and the Centre for Commercializing of Regenerative Medicine (CCRM)

BlueRock has partnerships with Memorial Sloan Kettering Cancer Center and Toronto-based Centre for Commercialization of Regenerative Medicine (CCRM).

The McEwen Stem Cell Institute

In December 2018, BlueRock partnered with The McEwen Stem Cell Institute at the University Health Network (UHN) in Toronto’s MaRS Discovery District. A new pilot Good Manufacturing Practices (GMP) facility will open in 2019.

Funding

Series A

On December 12, 2016 BlueRock Therapeutics completed their series A funding round with $225 million in funding from Versant Ventures and Bayer AG. 

Timeline

December 2016

Versant Ventures and Bayer provided US$225-million in financing to establish BlueRock Therapeutics

People

Name
Role
LinkedIn

Emile Nuwaysir, Ph.D.

President and CEO



Gordon Keller, Ph.D.

Scientific Founder



Lorenz Studer, M.D.

Scientific Founder



Michael A. Laflamme, M.D., Ph.D.

Founding Investigator



Robert Deans, Ph.D.

CTO



Viviane Tabar, M.D.

Founding Investigator



Further reading

Title
Author
Link
Type
Date

$225M BlueRock Therapeutics "monster" a magnet for Canada's biotech sector

Financial Post

News



BlueRock Therapeutics Strengthens Collaboration with the McEwen Stem Cell Institute

BlueRock Therapeutics

Web



BlueRock Therapeutics: A regenerative medicine game-changer

Invest Ontario

Web



What You Need to Know About BlueRock Therapeutics

Mark Terry

Web



Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









References